SEC Company Response from Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166) (BGMS) — Jan 15, 2013
Cyclacel Pharmaceuticals, Inc. (BGMS, BGMSP) (CIK 0001130166)
Date: Jan. 15, 2013 · CIK: 0001130166 · Accession: 0001104659-13-002624
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-185674
Letter
Re: Cyclacel Pharmaceuticals, Inc.
Cyclacel Pharmaceuticals, Inc.
200 Connell Drive, Suite 1500
Berkeley Heights, NJ 07922
January 15, 2013
Via EDGAR
Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549
Registration Statement on Form S-1, as amended
Originally Filed on December 26, 2012
File No. 333-185674
Ladies and Gentleman:
Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement to Form S-1, as amended, be accelerated to Wednesday, January 16, 2013, at 09:30 a.m., EST, or as soon as thereafter practicable.
Please note that we acknowledge the following:
· should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing;
· the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and
· the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States.
Any questions should be addressed to Merav Gershtenman, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 935-3000.
Thank you very much.
Very truly yours,
CYCLACEL PHARMACEUTICALS, INC.
Show Raw Text
CORRESP 1 filename1.htm Cyclacel Pharmaceuticals, Inc. 200 Connell Drive, Suite 1500 Berkeley Heights, NJ 07922 January 15, 2013 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Mail Stop 3561 Washington, D.C. 20549 Re: Cyclacel Pharmaceuticals, Inc. Registration Statement on Form S-1, as amended Originally Filed on December 26, 2012 File No. 333-185674 Ladies and Gentleman: Pursuant to Rule 461 of the Rules and Regulations promulgated under the Securities Act of 1933, as amended, Cyclacel Pharmaceuticals, Inc. (the “Company”) hereby requests that the effectiveness of the above-captioned Registration Statement to Form S-1, as amended, be accelerated to Wednesday, January 16, 2013, at 09:30 a.m., EST, or as soon as thereafter practicable. Please note that we acknowledge the following: · should the Commission or the staff, acting pursuant to delegated authority, declare the filing effective, it does not foreclose the Commission from taking any action with respect to the filing; · the action of the Commission or the staff, acting pursuant to delegated authority, in declaring the filing effective, does not relieve the Company from its full responsibility for the adequacy and accuracy of the disclosure in the filing; and · the Company may not assert staff comments and the declaration of effectiveness as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. Any questions should be addressed to Merav Gershtenman, Esq., at Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C., Chrysler Center, 666 Third Avenue, New York, New York 10017, telephone (212) 935-3000. Thank you very much. Very truly yours, CYCLACEL PHARMACEUTICALS, INC. /s/Paul McBarron Paul McBarron Executive Vice President—Finance, Chief Financial Officer and Chief Operating Officer cc: Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. Joel I. Papernik, Esq.